Modra Pharmaceuticals B.V.
About Modra Pharmaceuticals B.V.Modra Pharmaceuticals is contributing to modern cancer treatment options by improving the delivery and bioavailability of chemotherapy, the backbone of oncology regimens today. Through our oral formulation technology, we can bypass limitations of IV-delivered drugs, enabling a better product for patients. Our pipeline includes two of the most broadly used chemotherapies, docetaxel and paclitaxel, which we will advance rapidly through clinical evaluation. Our vision is to work together with cancer leaders and innovators to be an integral part of the rapidly evolving landscape of combination therapy and expedite the development of next-generation cancer regimens.
CEO: Eric van der Putten
Please click here for Modra Pharma job opportunities.
7 articles with Modra Pharmaceuticals B.V.
Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development
Modra Pharmaceuticals announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board.
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Data Include Positive Safety and Tolerability Profile, and Preliminary Efficacy Results for Boosted Oral Formulation of Docetaxel
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
Study will test efficacy and tolerability of novel docetaxel-based oral chemotherapeutic ModraDoc006/r
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
Study will test efficacy and safety of novel docetaxel-based oral therapeutic
-- Colin Freund has joined as CEO; Dr. Edwin De Wit appointed Head of Oncology Development --
Modra Pharma Announces Start Of Phase II Study For Its Lead Oral Chemotherapy In Patients With Metastatic Prostate Cancer